2026-06-30T02:01:42Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/178612024-09-21T19:46:10Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Fuente-Martín, Esther author Mellado-Gil, Jose M author Cobo-Vuilleumier, Nadia author Martín-Montalvo, Alejandro author Romero-Zerbo, Silvana Y author Diaz Contreras, Irene author Hmadcha, Abdelkrim author Soria, Bernat author Martin Bermudo, Francisco author Reyes, Jose C author Bermúdez-Silva, Francisco J author Lorenzo, Petra I author Gauthier, Benoit R 2024-02-10T20:01:28Z 2024-02-10T20:01:28Z 2019-05-08 10.3390/genes10050350 2073-4425 Genes http://hdl.handle.net/10668/13931 31072002 http://hdl.handle.net/20.500.12105/17861 The high prevalence of type 2 diabetes mellitus (T2DM), together with the fact that current treatments are only palliative and do not avoid major secondary complications, reveals the need for novel approaches to treat the cause of this disease. Efforts are currently underway to identify therapeutic targets implicated in either the regeneration or re-differentiation of a functional pancreatic islet β-cell mass to restore insulin levels and normoglycemia. However, T2DM is not only caused by failures in β-cells but also by dysfunctions in the central nervous system (CNS), especially in the hypothalamus and brainstem. Herein, we review the physiological contribution of hypothalamic neuronal and glial populations, particularly astrocytes, in the control of the systemic response that regulates blood glucose levels. The glucosensing capacity of hypothalamic astrocytes, together with their regulation by metabolic hormones, highlights the relevance of these cells in the control of glucose homeostasis. Moreover, the critical role of astrocytes in the response to inflammation, a process associated with obesity and T2DM, further emphasizes the importance of these cells as novel targets to stimulate the CNS in response to metabesity (over-nutrition-derived metabolic dysfunctions). We suggest that novel T2DM therapies should aim at stimulating the CNS astrocytic response, as well as recovering the functional pancreatic β-cell mass. Whether or not a common factor expressed in both cell types can be feasibly targeted is also discussed. eng T2DM Astrocytes Inflammation Metabesity Obesity Pancreatic islet Dissecting the Brain/Islet Axis in Metabesity. research article